The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53
Open accessAbstract
Tumour-derived p53 mutants are thought to have acquired 'gain-of-function' properties that contribute to oncogenicity. We have tested the hypothesis that p53 mutants suppress p53-target gene expression, leading to enhanced cellular growth. Silencing of mutant p53 expression in several human cell lines was found to lead to the upregulation of wild-type p53-target genes such as p21, gadd45, PERP and PTEN. The expression of these genes was also suppressed in H1299-based isogenic cell lines expressing various hot-spot p53 mutants, and silencing of mutant p53, but not TAp73, abrogated the suppression. Consistently, these hot-spot p53 mutants were able to suppress a variety of p53-target gene promoters. Analysis using the proto-type p21 promoter construct indicated that the p53-binding sites are dispensable for mutant p53-mediated suppression. However, treatment with the histone deacetylase inhibitor trichostatin-A resulted in relief of mutant p53-mediated suppression, suggesting that mutant p53 may induce hypo-acetylation of target gene promoters leading to the suppressive effects. Finally, we show that stable down-regulation of mutant p53 expression resulted in reduced cellular colony growth in human cancer cells, which was found to be due to the induction of apoptosis. Together, the results demonstrate another mechanism through which p53 mutants could promote cellular growth.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, GOF mut-p53 has been shown to abnormally regulate a multitude of genes that play critical roles in GBM pathogenesis, but have not been analyzed in the context of GBM. This includes CD95/Fas/Apo1, PARP, PTEN, and more [63,94,95,96,97,98].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [98]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · cited 2×
“Mutations in p53 have been shown to abrogate its cardinal functions in promoting apoptosis, cell-cycle arrest and DNA repair, thereby leading to cancer development and progression (1, 2 ).”
BackgroundMdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
A System for Stable Expression of Short Interfering RNAs in Mammalian Cells
Brummelkamp, T. R., Bernards, R., & Agami, R. (2002) · Science · doi:10.1126/science.1068999 · Cited by 4,295
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 2×
“Mutated p53 is often overexpressed in tumour cells (1,2,6), due to their inability to effectively activate MDM2, which negatively regulates p53 abundance (7,8).”
BackgroundLive or let die: the cell's response to p53
Vousden, K. H., & Lü, X. (2002) · Nature reviews. Cancer · doi:10.1038/nrc864 · Cited by 3,231
p300/CBP proteins: HATs for transcriptional bridges and scaffolds
Chan, H. M., & La Thangue, N. B. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.13.2363 · Cited by 1,092
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067
Role for the p53 homologue p73 in E2F-1-induced apoptosis
Irwin, M. S., Marín, M. C., Phillips, A. C., Seelan, R. S., Smith, D. I., Liu, W., Flores, E. R., Tsai, K. Y., Jacks, T., Vousden, K. H., et al. (2000) · Nature · doi:10.1038/35036614 · Cited by 710
Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
Sigal, A., & Rotter, V. (2000) · PubMed · Cited by 669
Mutations truncating the EP300 acetylase in human cancers
Gayther, S. A., Batley, S. J., Linger, L., Bannister, A. J., Thorpe, K. L., Chin, S., Daigo, Y., Russell, P. A., Wilson, A., Sowter, H., et al. (2000) · Nature Genetics · doi:10.1038/73536 · Cited by 588
Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues.
El‐Deiry, W. S., Tokino, T., Waldman, T. A., Oliner, J., Velculescu, V. E., Burrell, M., HILL, D. E., Healy, E., Rees, J. L., & Hamilton, S. R. (1995) · PubMed · Cited by 582
A common polymorphism acts as an intragenic modifier of mutant p53 behaviour
Marín, M. C., Jost, C. A., Brooks, L. A., Irwin, M. S., O’Nions, J., TIDY, J. A., James, N. D., McGregor, J., Harwood, C. A., Yuluğ, I. G., et al. (2000) · Nature Genetics · doi:10.1038/75586 · Cited by 511
Murphy, M. E., Ahn, J., Walker, K. K., Hoffman, W. H., Evans, R. M., Levine, A. J., & George, D. L. (1999) · Genes & Development · doi:10.1101/gad.13.19.2490 · Cited by 455
Bergamaschi, D., Gasco, M., Hiller, L., Sullivan, A., Syed, N., Trigiante, G., Yuluğ, I. G., Merlano, M. C., Numico, G., Comino, A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00079-5 · Cited by 445
DNA Damage-Dependent Acetylation of p73 Dictates the Selective Activation of Apoptotic Target Genes
Costanzo, A., Merlo, P., Pediconi, N., Fulco, M., Sartorelli, V., Cole, P. A., Fontemaggi, G., Fanciulli, M., Schiltz, L., Blandino, G., et al. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00431-8 · Cited by 317
Xu, D., Wang, Q., Gruber, A., Björkholm, M., Chen, Z., Zaid, A., Selivanova, G., Peterson, C., Wiman, K. G., & Pisa, P. (2000) · Oncogene · doi:10.1038/sj.onc.1203890 · Cited by 257
Mutant p53 Cooperates with ETS and Selectively Up-regulates Human MDR1 Not MRP1
Sampath, J., Sun, D., Kidd, V. J., Grenet, J., Gandhi, A., Shapiro, L. H., Wang, Q., Zambetti, G. P., & Schuetz, J. D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103429200 · Cited by 244
TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer.
Olivier, M., Hussain, S. P., de Fromentel, C. C., Hainaut, P. L., & Harris, C. C. (2004) · PubMed · Cited by 243
Physical and Functional Interaction between p53 Mutants and Different Isoforms of p73
Strano, S., Munarriz, E. R., Rossi, M., Cristofanelli, B., Shaul, Y., Castagnoli, L., Levine, A. J., Sacchi, A., Cesareni, G., Oren, M., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003360200 · Cited by 241
Bossi, G., Lapi, E., Strano, S., Rinaldo, C., Blandino, G., & Sacchi, A. (2005) · Oncogene · doi:10.1038/sj.onc.1209026 · Cited by 202
Frazier, M. W., He, X., Wang, J., Gu, Z., Cleveland, J. L., & Zambetti, G. P. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.3735 · Cited by 194
Hirose, T., Sowa, Y., Takahashi, S., Saito, S., Yasuda, C., Shindo, N., Furuichi, K., & Sakai, T. (2003) · Oncogene · doi:10.1038/sj.onc.1207091 · Cited by 128
Trp53-dependent DNA-repair is affected by the codon 72 polymorphism
Siddique, M. M., & Sabapathy, K. (2006) · Oncogene · doi:10.1038/sj.onc.1209405 · Cited by 128
Self-citationSmall molecules that reactivate mutant p53
Bykov, V. J. N., Selivanova, G., & Wiman, K. G. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00454-4 · Cited by 123
Zalcenstein, A., Stambolsky, P., Weisz, L., Müller, M., Wallach, D., Goncharov, T. M., Krammer, P. H., Rotter, V., & Oren, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206724 · Cited by 123
Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes
Scian, M. J., Stagliano, K. E., Deb, D., Ellis, M. A., Carchman, E. H., Das, A., Valerie, K. C., Deb, S. P., & Deb, S. (2004) · Oncogene · doi:10.1038/sj.onc.1207553 · Cited by 119
Modulation of Gene Expression by Tumor-Derived p53 Mutants
Scian, M. J., Stagliano, K. E., Ellis, M. A., Hassan, S., Bowman, M., Miles, M. F., Deb, S. P., & Deb, S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1568 · Cited by 117
Kakudo, Y., Shibata, H., Otsuka, K., Kato, S., & Ishioka, C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2935 · Cited by 88
Moon, W. S., Chang, K. S. S., & Tarnawski, A. S. (2004) · Human Pathology · doi:10.1016/j.humpath.2003.11.007 · Cited by 88
Mutant p53: Gain-of-Function Oncoproteins and Wild-Type p53 Inactivators
Roemer, K. (1999) · Biological Chemistry · doi:10.1515/bc.1999.108 · Cited by 86
Depletion of Mutant p53 and Cytotoxicity of Histone Deacetylase Inhibitors
Blagosklonny, M. V., Trostel, S. Y., Kayastha, G., Demidenko, Z. N., Vassilev, L. T., Romanova, L. Y., Bates, S. E., & Fojo, T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3433 · Cited by 83
Mutant p53 proteins bind DNA in a DNA structure-selective mode
hler, T. G. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki252 · Cited by 76
Vikhanskaya, F., Siddique, M. M., Lee, M. K., Broggini, M., & Sabapathy, K. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1547 · Cited by 75
Self-citationLee, M. K., Hande, M. P., & Sabapathy, K. (2005) · Journal of Cell Science · doi:10.1242/jcs.01673 · Cited by 69
Self-citationInduction of gene amplification as a gain-of-function phenotype of mutant p53 proteins.
El-Hizawi, S., Lagowski, J. P., Kulesz-Martin, M. F., & Albor, A. (2002) · PubMed · Cited by 56
Yang, X., Pater, A., & Tang, S. (1999) · Oncogene · doi:10.1038/sj.onc.1202843 · Cited by 50
Tan, G., Li, H., Jiang-bo, C., Ming, J., Yanhong, M., Xianghe, L., Hong, S. M., & Li, G. (2001) · International Journal of Cancer · doi:10.1002/ijc.1591 · Cited by 49
Relief of p53-mediated Telomerase Suppression by p73
Toh, W. H., Kyo, S., & Sabapathy, K. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500044200 · Cited by 29
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Apoptosis in cancer: from pathogenesis to treatment
Wong, R. S. (2011) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-30-87 · Cited by 2,836
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545
When mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132
Mutant p53 Gain-of-Function in CancerPreprint
Oren, M., & Rotter, V. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001107 · Cited by 778
IGF binding proteins in cancer: mechanistic and clinical insights
Baxter, R. C. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3720 · Cited by 525
Metadata
- Authors
- Vikhanskaya, F., Lee, M. K., Mazzoletti, M., Broggini, M., & Sabapathy, K.
- Affiliations
- National Cancer Centre Singapore (SG)
- National University of Singapore (SG)
- Corresponding author
- Sabapathy, K.
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-03-01
- Volume
- 35
- Issue
- 6
- Pages
- 2093-2104
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- PMC
- PMC1874625
- OpenAlex
- W2111523470
- Cited by
- 145
- References
- 38
- Citations by year
- 2026: 3 · 2025: 11 · 2024: 8 · 2023: 6 · 2022: 6 · 2021: 4 · 2020: 8 · 2019: 6 · 2018: 9 · 2017: 9 · 2016: 12 · 2015: 10 · 2014: 12 · 2013: 11 · 2012: 4
- FWCI
- 3.21
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- Nucleic Acids Research (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- National University of Singapore (submittedVersion)
- Funders
- Medical Research Council
- National Medical Research Council
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Keywords
- mutant p53, gain-of-function, p21, GADD45, PERP, PTEN, p53 binding sites, histone deacetylation, trichostatin A, apoptosis, cell growth, TAp73
- MeSH terms
- Binding Sites, Enzyme Inhibitors, Humans, Hydroxamic Acids, Mutation, Neoplasms, Promoter Regions, Genetic, Down-Regulation, Gene Expression Regulation, Neoplastic, Genes, p53, Tumor Suppressor Protein p53, Apoptosis, RNA Interference, Cell Line, Tumor, Cyclin-Dependent Kinase Inhibitor p21, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
